ES2102675T3 - Virus obtenible de celulas de neuroblastoma humanas. - Google Patents
Virus obtenible de celulas de neuroblastoma humanas.Info
- Publication number
- ES2102675T3 ES2102675T3 ES93919173T ES93919173T ES2102675T3 ES 2102675 T3 ES2102675 T3 ES 2102675T3 ES 93919173 T ES93919173 T ES 93919173T ES 93919173 T ES93919173 T ES 93919173T ES 2102675 T3 ES2102675 T3 ES 2102675T3
- Authority
- ES
- Spain
- Prior art keywords
- virus
- cells
- human
- rna
- neuroblastoma cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title abstract 7
- 206010029260 Neuroblastoma Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000003321 amplification Effects 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000000933 neural crest Anatomy 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
LA INVENCION PROPORCIONA UN VIRUS DE ESTRUCTURA ICOSAHEDRAL QUE TIENE UN DIAMETRO DE UNOS 72 NM, RNA DE DOBLE TRENZADO EN SIETE SEGMENTOS DE PESOS MOLECULARES 4''0, 3''9, 2''3, 2''2, 1''6, 1''4 Y 1''3 KB, CAPACES DE INFECTAR CELULAS DE CRESTA NEURAL HUMANA Y OTRAS CELULAS ECTODERMALES HUMANAS, ORIGINA AMPLIFICACION N-MYC EN CELULAS INFECTADAS, Y ES OBTENIBLE DE CELULAS NEUROBLASTOMAS HUMANAS. LA INVENCION PROPORCIONA ADEMAS EL RNA DEL VIRUS Y EL DNA CORRESPONDIENTE AL MISMO, ASI COMO FRAGMENTOS DEL MISMO Y LINEAS CELULARES TRANSFERIDAS CON EL VIRUS. ANTIGENOS DE USO EN VACUNAS PUEDEN COMPRENDER FORMAS ATENUADAS O INACTIVAS DEL VIRUS. LA INVENCION SE EXTIENDE TAMBIEN A ANTICUERPOS CONTRA EL VIRUS Y EQUIPOS DE DIAGNOSTICOS PARA ENSAYO DE VIRUS, COMPRENDIENDO TALES ANTICUERPOS O ANTIGENO VIRAL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9218164A GB9218164D0 (en) | 1992-08-26 | 1992-08-26 | Virus and substances related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2102675T3 true ES2102675T3 (es) | 1997-08-01 |
Family
ID=10721003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES93919173T Expired - Lifetime ES2102675T3 (es) | 1992-08-26 | 1993-08-25 | Virus obtenible de celulas de neuroblastoma humanas. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0658195B1 (es) |
| JP (1) | JPH08505760A (es) |
| AT (1) | ATE153375T1 (es) |
| AU (1) | AU681352B2 (es) |
| CA (1) | CA2142902A1 (es) |
| DE (1) | DE69310918T2 (es) |
| DK (1) | DK0658195T3 (es) |
| ES (1) | ES2102675T3 (es) |
| GB (1) | GB9218164D0 (es) |
| GR (1) | GR3024494T3 (es) |
| IL (1) | IL106793A0 (es) |
| WO (1) | WO1994004661A1 (es) |
| ZA (1) | ZA936163B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060040882A1 (en) | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
| AU2006304291A1 (en) * | 2005-10-14 | 2007-04-26 | Marina Biotech, Inc. | Compounds and methods for peptide ribonucleic acid condensate particles for RNA therapeutics |
-
1992
- 1992-08-26 GB GB9218164A patent/GB9218164D0/en active Pending
-
1993
- 1993-08-23 ZA ZA936163A patent/ZA936163B/xx unknown
- 1993-08-24 IL IL106793A patent/IL106793A0/xx unknown
- 1993-08-25 JP JP50592494A patent/JPH08505760A/ja active Pending
- 1993-08-25 ES ES93919173T patent/ES2102675T3/es not_active Expired - Lifetime
- 1993-08-25 CA CA 2142902 patent/CA2142902A1/en not_active Abandoned
- 1993-08-25 AU AU49534/93A patent/AU681352B2/en not_active Ceased
- 1993-08-25 DK DK93919173T patent/DK0658195T3/da active
- 1993-08-25 AT AT93919173T patent/ATE153375T1/de active
- 1993-08-25 EP EP19930919173 patent/EP0658195B1/en not_active Expired - Lifetime
- 1993-08-25 WO PCT/EP1993/002291 patent/WO1994004661A1/en active IP Right Grant
- 1993-08-25 DE DE69310918T patent/DE69310918T2/de not_active Expired - Fee Related
-
1997
- 1997-08-21 GR GR970402133T patent/GR3024494T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08505760A (ja) | 1996-06-25 |
| EP0658195B1 (en) | 1997-05-21 |
| CA2142902A1 (en) | 1994-03-03 |
| AU4953493A (en) | 1994-03-15 |
| GB9218164D0 (en) | 1992-10-14 |
| DK0658195T3 (da) | 1997-07-14 |
| WO1994004661A1 (en) | 1994-03-03 |
| DE69310918T2 (de) | 1997-12-18 |
| EP0658195A1 (en) | 1995-06-21 |
| IL106793A0 (en) | 1993-12-08 |
| ZA936163B (en) | 1995-02-03 |
| GR3024494T3 (en) | 1997-11-28 |
| ATE153375T1 (de) | 1997-06-15 |
| AU681352B2 (en) | 1997-08-28 |
| DE69310918D1 (de) | 1997-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy | |
| Walls et al. | Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines | |
| Wang et al. | Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies | |
| Warfield et al. | Ebola virus-like particles protect from lethal Ebola virus infection | |
| Deeba et al. | Chikungunya virus: recent advances in epidemiology, host pathogen interaction and vaccine strategies | |
| Hawman et al. | Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response | |
| Khan et al. | Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice | |
| ES2126620T3 (es) | Retrovirus del grupo de los vih y su utilizacion. | |
| Walsh et al. | Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus | |
| Valkenburg et al. | IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection | |
| DE69637642D1 (de) | Und kombinierte zusammensetzungen und deren verwendung | |
| ES2143507T3 (es) | Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia. | |
| ES2154738T3 (es) | Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora. | |
| ES2083764T3 (es) | Vacuna contra el sindrome respiratorio reproductivo porcino (srrp) y diagnostico. | |
| CO4480039A1 (es) | Vacunas recombinantes de inmunodeficiencia felina producidas en baculovirus y su uso contra la infeccion de virus de inmunodeficiencia felina | |
| Ahmed et al. | Inactivated vaccine Covaxin/BBV152: A systematic review | |
| Zhu et al. | A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine | |
| PE72699A1 (es) | Antigeno del rotavirus, vacuna y agente diagnostico para infeccion por rotavirus y un metodo para producir el antigeno | |
| Ahmed et al. | Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections | |
| Ai et al. | Antibody resistance of SARS-CoV-2 Omicron BA. 1, BA. 1.1, BA. 2 and BA. 3 sub-lineages | |
| Mandal | Achievements of the COVID-19 Turkey Platform in vaccine and drug development withan approach of" co-creation and succeeding together" | |
| ES2102675T3 (es) | Virus obtenible de celulas de neuroblastoma humanas. | |
| CO5721019A2 (es) | Aislados y vacunas antigenicos de virus de bursitis infecciosa | |
| Taylor et al. | Live, attenuated Venezuelan equine encephalitis virus vaccine (TC83) causes persistent brain infection in mice with non-functional αβ T-cells | |
| ATE283065T1 (de) | Mehrzweckvakzine gegen umhüllte viren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 658195 Country of ref document: ES |